21 September 2022

VIVEbiotech, one of the three only companies to obtain a PERTE

VIVEbiotech has obtained the PERTE called “Salud de Vanguardia/State-Of-The-Art Health” by the Ministry of Industry of the Spanish Government which is financed with European...

Read more

21 June 2022

VIVEbiotech continues the expansion of its lentiviral vector manufacturing capabilities to address the viral vector bottleneck

VIVEbiotech, a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces its Good Manufacturing Practice (GMP)-accredited...

Read more

4 May 2022

Interview with Natalia Elizalde in The Medicine Maker

The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.

Read more

2 May 2022

Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022

The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List

Read more

7 April 2022

The Analytical Scientist interviews Rakel Lopez de Maturana

The Analytical Scientist interviewed Rakel Lopez de Maturana, VIVEbiotech´s Qualified Person & Regulatory Affairs Director.

Read more

9 March 2022

PharmaBoardroom interviews Gurutz Linazasoro, CEO of VIVEbiotech

PharmaBoardroom, the global platform for healthcare & life sciences executives, interviewed Gurutz Linazasoro, CEO of VIVEbiotech.

Read more

18 February 2022

VIVEbiotech receives the “LH Duala Euskaraz” award

VIVEbiotech has been awarded with the “LH Duala Euskaraz” prize for promoting the use of Euskara, the language of the Basque Country, on a regular...

Read more

2 February 2022

PharmaBoardoom points out VIVEbiotech as one of the ten Spanish Biotechs to watch in 2022

PharmaBoardroom, a leading British media specialized in the health sector, has published an article in which it highlights VIVEbiotech as one of the ten Spanish...

Read more

5 January 2022

Article on improving viral vector production in GEN

GEN recently interviewed our Business Development Director, Dr. Natalia Elizalde, with whom they spoke about improving the production of lentiviral vectors, vectors that VIVEbiotech develops...

Read more